Tocilizumab and sarilumab, monoclonal antibodies targeting the IL-6 receptor, and siltuximab, a chimeric antibody targeting IL-6, are currently being investigated for the treatment of patients with COVID-19 and ARDS complications; the potential of tocilizumab to curb the cytokine storm was reported in a retrospective study of a small number of patients (n = 21) in China with severe/critical COVID-19 who underwent treatment with the anti-IL-6 monoclonal antibody tocilizumab. Here, IL6 is linked to acute respiratory distress syndrome.